Drs Banu Arun and Avan J. Armaghani discuss the evolving treatment landscape of targeted therapy for advanced and metastatic breast cancer, including risk factors, quality of life, and treatment access.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982651). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer https://emedicine.medscape.com/article/1947145-overview

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview#:~:text=Metastatic%20Breast%20Cancer-,Practice%20Essentials,20%25%20of%20invasive%20breast%20cancers.

Personalized Medicine https://www.genome.gov/genetics-glossary/Personalized-Medicine

Emerging Digital Technologies in Cancer Treatment, Prevention, and Control https://pubmed.ncbi.nlm.nih.gov/34850933/

Introduction to Antibody-drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Antibody-drug Conjugates and Subgroups of Advanced and Metastatic Breast Cancer: Strategies, Resistance, Emerging Data https://www.medscape.com/viewarticle/982644 

Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-of-study Results From a Double-blind, Randomised, Placebo-controlled, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/32171426/

Trastuzumab Deruxtecan in Previously Treated HER2-positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/31825192/

Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in Patients With HER2-positive Metastatic Breast Cancer: Updated Results From DESTINY-Breast03, a Randomised, Open-label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/36495879/

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) https://clinicaltrials.gov/ct2/show/NCT04784715

Targeting HER3 for Cancer Treatment: A New Horizon for an Old Target https://pubmed.ncbi.nlm.nih.gov/36764093/

A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients With Pretreated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis https://pubmed.ncbi.nlm.nih.gov/34954044/

Progression-free Survival: What Does It Mean for Psychological Well-being or Quality of Life? https://www.ncbi.nlm.nih.gov/books/NBK137763/

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) https://clinicaltrials.gov/ct2/show/NCT04539938

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) https://clinicaltrials.gov/ct2/show/NCT05132582

Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/

Drs Banu Arun and Stephanie Graff discuss drug access, clinical trials, and health disparities in advanced and metastatic breast cancer, and inclusion-based solutions for physicians and institutions.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982650). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer https://emedicine.medscape.com/article/1947145-overview

A Review of Triple-Negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

Oral Selective Estrogen Receptor Degraders (SERDS) as a Novel Breast Cancer Therapy: Present and Future From a Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/34360578/

Introduction to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Sacituzumab Govitecan (Rx) https://reference.medscape.com/drug/trodelvy-sacituzumab-govitecan-1000280

Trastuzumab Deruxtecan (Rx) https://reference.medscape.com/drug/enhertu-trastuzumab-deruxtecan-4000032

T-DM1 https://www.cancer.gov/publications/dictionaries/cancer-terms/def/t-dm1

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update https://pubmed.ncbi.nlm.nih.gov/31928404/

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 https://pubmed.ncbi.nlm.nih.gov/31415071/

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/

Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35320644/

I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33312344/

Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/35280480/

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement https://pubmed.ncbi.nlm.nih.gov/35588469/

Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment https://pubmed.ncbi.nlm.nih.gov/36630663/

An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials https://pubmed.ncbi.nlm.nih.gov/36630671/

The Implicit Association Test in Health Professions Education: A Meta-Narrative Review https://pubmed.ncbi.nlm.nih.gov/31535290/

Increasing Black Patient Participation in Metastatic Breast Cancer Clinical Trials: The BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement) Project https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1014#

Achieving Culturally Competent Cancer Care: A Qualitative Study Drawing on the Perspectives of Cancer Survivors and Oncology Nurses https://pubmed.ncbi.nlm.nih.gov/31841798/

Drs Banu Arun and Hope S. Rugo discuss immunotherapy, immunotoxicity, and comorbidities among diverse patient populations in advanced and metastatic breast cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982649). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

The Emerging CDK4/6 Inhibitor for Breast Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/35251463/

Endocrine Therapy Combined With Targeted Therapy in Hormone Receptor-positive Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32852380/

Introduction to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Trastuzumab Deruxtecan for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35704495/

Triple Negative Breast Cancer: A Thorough Review of Biomarkers https://pubmed.ncbi.nlm.nih.gov/31927455/

Immunotherapy in Breast Cancer: An Overview of Current Strategies and Perspectives https://pubmed.ncbi.nlm.nih.gov/36781869/

Post-neoadjuvant Treatment Strategies in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35267554/

PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/

PD-1/PD-L1 Pathway: Current Researches in Cancer https://pubmed.ncbi.nlm.nih.gov/32266087/

Checkpoint Blockade in the Treatment of Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/29808015/

Neoantigens: Promising Targets for Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/36604431/

Atezolizumab and Nab-paclitaxel in Advanced Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30345906/

Nab-paclitaxel Dose and Schedule in Breast Cancer https://www.medscape.com/viewarticle/849295

VENTANA PD-L1 (SP142) Assay https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160002c.pdf

Primary Results From IMpassion131, a Double-blind, Placebo-controlled, Randomised Phase III Trial of First-line Paclitaxel With or Without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34219000/

Pembrolizumab Plus Chemotherapy in Advanced Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35857659/

Gemcitabine and Carboplatin for Pretreated Metastatic Breast Cancer: The Predictive Value of Immunohistochemically Defined Subtypes https://pubmed.ncbi.nlm.nih.gov/22350024/

PD-L1 IHC 22C3 PharmDx https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150013c.pdf

Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/

18th St. Gallen International Breast Cancer Conference 2023 https://www.oncoconferences.ch/events/sgbcc-2023/

Prognostic and Predictive Value of Immune-related Gene Expression Signatures vs Tumor-infiltrating Lymphocytes in Early-stage ERBB2/HER2-positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials https://pubmed.ncbi.nlm.nih.gov/36602784/

Molecular Subtypes and Imaging Phenotypes of Breast Cancer https://pubmed.ncbi.nlm.nih.gov/27599892/

I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-risk Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33312344/

Luminal B Breast Cancer: Patterns of Recurrence and Clinical Outcome https://pubmed.ncbi.nlm.nih.gov/27542253/

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) https://clinicaltrials.gov/ct2/show/NCT04895358

Utility of the CPS + EG Scoring System in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy https://pubmed.ncbi.nlm.nih.gov/34186505/